Seroatlas · Human Serome Atlas

TENM2

Teneurin-2

Also known as: KIAA1127, ODZ2, Ten-M2, TEN2, TEN2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9NT68
Gene: TENM2
Ensembl: ENSG00000145934
Chromosome: 5
Canonical length: 2774 aa
Protein class: Predicted intracellular proteins, Predicted membrane proteins, Transporters
Subcellular location: Nucleoli
Quaternary structure: Homodimer

OverviewNCBI Gene

Enables cell adhesion molecule binding activity and signaling receptor binding activity. Involved in retrograde trans-synaptic signaling by trans-synaptic protein complex. Located in cell-cell junction and plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

2774 residues, UniProt reviewed canonical sequence.

>Q9NT68|TENM2
     1  MDVKDRRHRS LTRGRCGKEC RYTSSSLDSE DCRVPTQKSY SSSETLKAYD HDSRMHYGNR
    61  VTDLIHRESD EFPRQGTNFT LAELGICEPS PHRSGYCSDM GILHQGYSLS TGSDADSDTE
   121  GGMSPEHAIR LWGRGIKSRR SSGLSSRENS ALTLTDSDNE NKSDDENGRP IPPTSSPSLL
   181  PSAQLPSSHN PPPVSCQMPL LDSNTSHQIM DTNPDEEFSP NSYLLRACSG PQQASSSGPP
   241  NHHSQSTLRP PLPPPHNHTL SHHHSSANSL NRNSLTNRRS QIHAPAPAPN DLATTPESVQ
   301  LQDSWVLNSN VPLETRHFLF KTSSGSTPLF SSSSPGYPLT SGTVYTPPPR LLPRNTFSRK
   361  AFKLKKPSKY CSWKCAALSA IAAALLLAIL LAYFIAMHLL GLNWQLQPAD GHTFNNGIRT
   421  GLPGNDDVAT MPSGGKVPWS LKNSSIDSGE AEVGRRVTQE VPPGVFWRSQ IHISQPQFLK
   481  FNISLGKDAL FGVYIRRGLP PSHAQYDFME RLDGKEKWSV VESPRERRSI QTLVQNEAVF
   541  VQYLDVGLWH LAFYNDGKDK EMVSFNTVVL DSVQDCPRNC HGNGECVSGV CHCFPGFLGA
   601  DCAKAACPVL CSGNGQYSKG TCQCYSGWKG AECDVPMNQC IDPSCGGHGS CIDGNCVCSA
   661  GYKGEHCEEV DCLDPTCSSH GVCVNGECLC SPGWGGLNCE LARVQCPDQC SGHGTYLPDT
   721  GLCSCDPNWM GPDCSVEVCS VDCGTHGVCI GGACRCEEGW TGAACDQRVC HPRCIEHGTC
   781  KDGKCECREG WNGEHCTIGR QTAGTETDGC PDLCNGNGRC TLGQNSWQCV CQTGWRGPGC
   841  NVAMETSCAD NKDNEGDGLV DCLDPDCCLQ SACQNSLLCR GSRDPLDIIQ QGQTDWPAVK
   901  SFYDRIKLLA GKDSTHIIPG ENPFNSSLVS LIRGQVVTTD GTPLVGVNVS FVKYPKYGYT
   961  ITRQDGTFDL IANGGASLTL HFERAPFMSQ ERTVWLPWNS FYAMDTLVMK TEENSIPSCD
  1021  LSGFVRPDPI IISSPLSTFF SAAPGQNPIV PETQVLHEEI ELPGSNVKLR YLSSRTAGYK
  1081  SLLKITMTQS TVPLNLIRVH LMVAVEGHLF QKSFQASPNL AYTFIWDKTD AYGQRVYGLS
  1141  DAVVSVGFEY ETCPSLILWE KRTALLQGFE LDPSNLGGWS LDKHHILNVK SGILHKGTGE
  1201  NQFLTQQPAI ITSIMGNGRR RSISCPSCNG LAEGNKLLAP VALAVGIDGS LYVGDFNYIR
  1261  RIFPSRNVTS ILELRNKEFK HSNNPAHKYY LAVDPVSGSL YVSDTNSRRI YRVKSLSGTK
  1321  DLAGNSEVVA GTGEQCLPFD EARCGDGGKA IDATLMSPRG IAVDKNGLMY FVDATMIRKV
  1381  DQNGIISTLL GSNDLTAVRP LSCDSSMDVA QVRLEWPTDL AVNPMDNSLY VLENNVILRI
  1441  TENHQVSIIA GRPMHCQVPG IDYSLSKLAI HSALESASAI AISHTGVLYI TETDEKKINR
  1501  LRQVTTNGEI CLLAGAASDC DCKNDVNCNC YSGDDAYATD AILNSPSSLA VAPDGTIYIA
  1561  DLGNIRIRAV SKNKPVLNAF NQYEAASPGE QELYVFNADG IHQYTVSLVT GEYLYNFTYS
  1621  TDNDVTELID NNGNSLKIRR DSSGMPRHLL MPDNQIITLT VGTNGGLKVV STQNLELGLM
  1681  TYDGNTGLLA TKSDETGWTT FYDYDHEGRL TNVTRPTGVV TSLHREMEKS ITIDIENSNR
  1741  DDDVTVITNL SSVEASYTVV QDQVRNSYQL CNNGTLRVMY ANGMGISFHS EPHVLAGTIT
  1801  PTIGRCNISL PMENGLNSIE WRLRKEQIKG KVTIFGRKLR VHGRNLLSID YDRNIRTEKI
  1861  YDDHRKFTLR IIYDQVGRPF LWLPSSGLAA VNVSYFFNGR LAGLQRGAMS ERTDIDKQGR
  1921  IVSRMFADGK VWSYSYLDKS MVLLLQSQRQ YIFEYDSSDR LLAVTMPSVA RHSMSTHTSI
  1981  GYIRNIYNPP ESNASVIFDY SDDGRILKTS FLGTGRQVFY KYGKLSKLSE IVYDSTAVTF
  2041  GYDETTGVLK MVNLQSGGFS CTIRYRKIGP LVDKQIYRFS EEGMVNARFD YTYHDNSFRI
  2101  ASIKPVISET PLPVDLYRYD EISGKVEHFG KFGVIYYDIN QIITTAVMTL SKHFDTHGRI
  2161  KEVQYEMFRS LMYWMTVQYD SMGRVIKREL KLGPYANTTK YTYDYDGDGQ LQSVAVNDRP
  2221  TWRYSYDLNG NLHLLNPGNS VRLMPLRYDL RDRITRLGDV QYKIDDDGYL CQRGSDIFEY
  2281  NSKGLLTRAY NKASGWSVQY RYDGVGRRAS YKTNLGHHLQ YFYSDLHNPT RITHVYNHSN
  2341  SEITSLYYDL QGHLFAMESS SGEEYYVASD NTGTPLAVFS INGLMIKQLQ YTAYGEIYYD
  2401  SNPDFQMVIG FHGGLYDPLT KLVHFTQRDY DVLAGRWTSP DYTMWKNVGK EPAPFNLYMF
  2461  KSNNPLSSEL DLKNYVTDVK SWLVMFGFQL SNIIPGFPRA KMYFVPPPYE LSESQASENG
  2521  QLITGVQQTT ERHNQAFMAL EGQVITKKLH ASIREKAGHW FATTTPIIGK GIMFAIKEGR
  2581  VTTGVSSIAS EDSRKVASVL NNAYYLDKMH YSIEGKDTHY FVKIGSADGD LVTLGTTIGR
  2641  KVLESGVNVT VSQPTLLVNG RTRRFTNIEF QYSTLLLSIR YGLTPDTLDE EKARVLDQAR
  2701  QRALGTAWAK EQQKARDGRE GSRLWTEGEK QQLLSTGRVQ GYEGYYVLPV EQYPELADSS
  2761  SNIQFLRQNE MGKR

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TENM2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0
Highest tissue expression: 33 nTPM

Expression across tissuesHPA

Tissue

heart muscle: 33 nTPM
cerebral cortex: 5.8 nTPM
basal ganglia: 4 nTPM
retina: 3.6 nTPM
hippocampal formation: 3.2 nTPM
skin: 3 nTPM

Single-cell type

retinal horizontal cells: 2,709 nCPM
brain excitatory neurons: 1,897 nCPM
brain inhibitory neurons: 1,690 nCPM
retinal ganglion cells: 1,673 nCPM
choroid plexus epithelial cells: 1,452 nCPM
thymic myoid cells: 1,353 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

cerebral cortex: 32 nTPM
hippocampal formation: 27 nTPM
basal ganglia: 24 nTPM
hypothalamus: 23 nTPM
amygdala: 16 nTPM
midbrain: 14 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.19
gnomAD pLI: 1
gnomAD missense Z: 3.3

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TENM2 as an antibody target. Whether an autoantibody or antibody against TENM2 could matter depends on whether native TENM2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TENM2 is annotated at the cell surface, where native TENM2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TENM2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...